A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions

Value in Health

Volumn 19, Issue 6, 2016, Pages 885-891

  Claxton, Karl ^a   Palmer, Stephen ^a   Longworth, Louise ^b   Bojke, Laura ^a   Griffin, Susan ^a   Soares, Marta ^a   Spackman, Eldon ^a   Rothery, Claire ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

cost effectiveness; coverage with evidence development; health technology assessment; only in research

Indexed keywords

ALGORITHM; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DEVICE APPROVAL; EVIDENCE BASED PRACTICE; MEDICAL TECHNOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DECISION MAKING; HEALTH INSURANCE; INSURANCE;

ALGORITHMS; BIOMEDICAL TECHNOLOGY; COST-BENEFIT ANALYSIS; DECISION MAKING; INSURANCE COVERAGE; INSURANCE, HEALTH; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84966648431     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.03.2003     Document Type: Article

References (29)

1. [1] European Medicines Agency. Human medicines research & development support: questions and answers following the initial experience of the Adaptive Licensing Pilot project 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500172810.pdf. [Accessed November 13, 2015].
2. [2] Baird, L.G., Banken, R., Eichler, H.G., et al. Accelerated access to innovative medicines for patients in need. Clin Pharmacol Therapeut 96 (2014), 559–571.
3. [3] Carlson, J., Sullivan, S., Garrison, L., et al. Linking Payment and Health Outcomes: A Systematic Review of Performance-Based Health. 2008, University of Washington, Washington.
4. [4] McCabe, C.J., Stafinski, T., Edlin, R., Menon, D., Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics 28 (2010), 143–152.
5. [5] Stafinski, T., McCabe, C.J., Menon, D., Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 28 (2010), 113–142.
6. [6] Towse, A., Garrison, L.P. Jr, Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 28 (2010), 93–102.
7. [7] Culyer, A., McCabe, C., Briggs, A., et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy 12 (2007), 56–58.
8. [8] Phelps, C.E., Mushlin, A.I., On the (near) equivalence of cost-effectiveness and cost-benefit analyses. Int J Technol Assess Health Care 7 (1991), 12–21.
9. [9] Stinnett, A.A., Mullahy, J., Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18:Suppl (1998), S68–S80.
10. [10] Claxton, K., Briggs, A., Buxton, M., et al. Value based pricing for NHS drugs: an opportunity not to be missed?. BMJ 336 (2008), 251–254.
11. [11] McCabe, C., Claxton, K., Culyer, A.J., The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26 (2008), 733–744.
12. [12] Claxton, K., The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 18 (1999), 342–364.
13. [13] Claxton, K., Cohen, J., Neumann, P., When is evidence sufficient?. Health Aff 24 (2005), 93–101.
14. [14] Claxton, K., Sculpher, M., Drummond, M., A rational framework for decision making by the National Institute for Clinical Excellence. Lancet 360 (2002), 711–715.
15. [15] Griffin, S.C., Claxton, K.P., Palmer, S.J., Sculpher, M.J., Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ 20 (2011), 212–224.
16. [16] Trueman, P., Grainger, D.L., Downs, K.E., Coverage with evidence development: applications and issues. Int J Technol Assess Health Care 26 (2010), 79–85.
17. [17] Philips, Z., Claxton, K., Palmer, S., The half-life of truth: what are appropriate time horizons for research decisions?. Med Decis Making 28 (2008), 287–299.
18. [18] Eckermann, S., Willan, A.R., The option value of delay in health technology assessment. Med Dec Making 28 (2008), 300–305.
19. [19] Fenwick, E., Claxton, K., Sculpher, M., The value of implementation and the value of information: combined and uneven development. Med Dec Making 28 (2008), 21–32.
20. [20] Hoomans, T., Fenwick, E.A., Palmer, S., Claxton, K., Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value Health 12 (2009), 315–324.
21. [21] McKenna, C., Claxton, K., Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis. Med Decis Making 31 (2011), 853–865.
22. [22] Palmer, S., Smith, P., Incorporating option values into the economic evaluation of health care technologies. J Health Econ 19 (2000), 755–766.
23. [23] Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford Medical Publications, Oxford University Press, 2015.
24. [24] Claxton, K., Palmer, S., Longworth, L., et al. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technol Assess 16 (2012), 1–323.
25. [25] McKenna, C., Soares, M., Claxton, K., et al. Unifying research and reimbursement decisions: case studies demonstrating the sequence of assessment and judgments required. Value Health 18 (2015), 865–875.
26. [26] Chalkidou, K., Lord, J., Fischer, A., Littlejohns, P., Evidence-based decision making: when should we wait for more information?. Health Aff 27 (2008), 1642–1653.
27. [27] Basu, A., Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. J Health Econ 30 (2011), 549–559.
28. [28] Jena, A.B., Philipson, T.J., Endogenous cost-effectiveness analysis and health care technology adoption. J Health Econ 32 (2013), 172–180.
29. [29] Claxton, K., OFT, VBP: QED?. Health Econ 16 (2007), 545–558.